GemPharmatech Co., Ltd. (688046.SS)
- Previous Close
11.31 - Open
11.31 - Bid 11.37 x --
- Ask 11.39 x --
- Day's Range
11.05 - 11.58 - 52 Week Range
9.08 - 17.70 - Volume
5,897,556 - Avg. Volume
4,021,934 - Market Cap (intraday)
4.662B - Beta (5Y Monthly) 0.47
- PE Ratio (TTM)
33.44 - EPS (TTM)
0.34 - Earnings Date --
- Forward Dividend & Yield 0.19 (1.68%)
- Ex-Dividend Date Nov 4, 2024
- 1y Target Est
--
GemPharmatech Co., Ltd., a contract research organization, provides genetically engineered mouse models and preclinical research services to the scientific community worldwide. The company offers mouse models, including knockout and conditional knockout mouse, disease mouse, immunodeficient mouse, germ-free mouse, and tool mice models, as well as operates wild mouse project. It also provides custom model generation, preclinical testing, germ-free and microbiome, cell lines and customization, custom breeding, animal quality testing, and other services. The company was founded in 2017 and is headquartered in Nanjing, China.
www.gempharmatech.comRecent News: 688046.SS
View MorePerformance Overview: 688046.SS
Trailing total returns as of 4/28/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 688046.SS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 688046.SS
View MoreValuation Measures
Market Cap
4.64B
Enterprise Value
3.69B
Trailing P/E
33.26
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
6.85
Price/Book (mrq)
2.18
Enterprise Value/Revenue
5.45
Enterprise Value/EBITDA
26.24
Financial Highlights
Profitability and Income Statement
Profit Margin
16.86%
Return on Assets (ttm)
--
Return on Equity (ttm)
5.45%
Revenue (ttm)
686.8M
Net Income Avi to Common (ttm)
115.79M
Diluted EPS (ttm)
0.34
Balance Sheet and Cash Flow
Total Cash (mrq)
1.21B
Total Debt/Equity (mrq)
5.36%
Levered Free Cash Flow (ttm)
--